MX2013001402A - Proceso para preparar tubulisinas. - Google Patents
Proceso para preparar tubulisinas.Info
- Publication number
- MX2013001402A MX2013001402A MX2013001402A MX2013001402A MX2013001402A MX 2013001402 A MX2013001402 A MX 2013001402A MX 2013001402 A MX2013001402 A MX 2013001402A MX 2013001402 A MX2013001402 A MX 2013001402A MX 2013001402 A MX2013001402 A MX 2013001402A
- Authority
- MX
- Mexico
- Prior art keywords
- processes
- tubulysins
- naturally occurring
- preparing
- preparing tubulysins
- Prior art date
Links
- 229930184737 tubulysin Natural products 0.000 title abstract 3
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000002254 cytotoxic agent Substances 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37143310P | 2010-08-06 | 2010-08-06 | |
| PCT/US2011/046797 WO2012019123A1 (en) | 2010-08-06 | 2011-08-05 | Processes for preparing tubulysins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2013001402A true MX2013001402A (es) | 2013-08-29 |
Family
ID=45559842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013001402A MX2013001402A (es) | 2010-08-06 | 2011-08-05 | Proceso para preparar tubulisinas. |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US8889880B2 (enExample) |
| EP (1) | EP2600866A4 (enExample) |
| JP (1) | JP2013535220A (enExample) |
| KR (1) | KR20130096712A (enExample) |
| CN (1) | CN103140227B (enExample) |
| AU (1) | AU2011285532B2 (enExample) |
| BR (1) | BR112013003004A2 (enExample) |
| CA (1) | CA2807511A1 (enExample) |
| EA (1) | EA025471B1 (enExample) |
| MX (1) | MX2013001402A (enExample) |
| SG (1) | SG187728A1 (enExample) |
| WO (1) | WO2012019123A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8288557B2 (en) | 2004-07-23 | 2012-10-16 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
| US20100104626A1 (en) | 2007-02-16 | 2010-04-29 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
| CN101678124A (zh) | 2007-03-14 | 2010-03-24 | 恩多塞特公司 | 结合配体连接的微管溶素递药缀合物 |
| US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
| CN101784565B (zh) | 2007-06-25 | 2014-12-10 | 恩多塞特公司 | 含有亲水性间隔区接头的共轭物 |
| CA2703491C (en) | 2007-10-25 | 2017-06-13 | Endocyte, Inc. | Tubulysins and processes for preparing |
| EP2600866A4 (en) * | 2010-08-06 | 2013-12-11 | Endocyte Inc | PROCESS FOR THE PRODUCTION OF TUBULYSINES |
| WO2013126797A1 (en) | 2012-02-24 | 2013-08-29 | Purdue Research Foundation | Cholecystokinin b receptor targeting for imaging and therapy |
| US20140080175A1 (en) * | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
| AU2013331440A1 (en) | 2012-10-16 | 2015-04-30 | Endocyte, Inc. | Drug delivery conjugates containing unnatural amino acids and methods for using |
| MY171561A (en) | 2012-11-15 | 2019-10-18 | Endocyte Inc | Conjugates for treating diseases caused by psma expressing cells |
| US20140249315A1 (en) | 2013-03-01 | 2014-09-04 | Endocyte, Inc. | Processes for preparing tubulysins |
| CN106132959B (zh) * | 2014-01-28 | 2020-04-17 | 管道制药有限责任公司 | 用于缀合的细胞毒性微管溶素化合物 |
| ES2819863T3 (es) | 2014-04-11 | 2021-04-19 | Medimmune Llc | Anticuerpos contra HER2 biespecíficos |
| CA2962783A1 (en) | 2014-10-01 | 2016-04-07 | Medimmune, Llc | Method of conjugating a polypeptide |
| KR20170137725A (ko) * | 2015-02-25 | 2017-12-13 | 윌리엄 마쉬 라이스 유니버시티 | 데스아세톡시투불리신 h 및 이의 유사체 |
| SG10202103712VA (en) | 2015-11-10 | 2021-05-28 | Medimmune Llc | Binding molecules specific for asct2 and uses thereof |
| US11229708B2 (en) | 2015-12-04 | 2022-01-25 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| WO2017132298A1 (en) | 2016-01-27 | 2017-08-03 | Medimmune, Llc | Methods for preparing antibodies with a defined glycosylation pattern |
| TWI781098B (zh) | 2016-04-15 | 2022-10-21 | 美商宏觀基因股份有限公司 | 新穎的ｂ７-ｈ３-結合分子、其抗體藥物綴合物及其使用方法 |
| AR111963A1 (es) | 2017-05-26 | 2019-09-04 | Univ California | Método y moléculas |
| JP7150820B2 (ja) | 2017-08-01 | 2022-10-11 | メディミューン，エルエルシー | Ｂｃｍａモノクローナル抗体薬剤コンジュゲート |
| US11274124B2 (en) | 2017-11-29 | 2022-03-15 | William Marsh Rice University | Tubulysin analogues as anticancer agents and payloads for antibody-drug conjugates and methods of treatment therewith |
| US11795225B2 (en) | 2020-09-11 | 2023-10-24 | Medimmune Limited | Therapeutic binding molecules |
| US11807685B2 (en) | 2021-08-05 | 2023-11-07 | The Uab Research Foundation | Anti-CD47 antibody and uses thereof |
| EP4429765A1 (en) | 2021-11-10 | 2024-09-18 | Astrazeneca AB | Antibody molecules and conjugates |
| GB202117928D0 (en) | 2021-12-11 | 2022-01-26 | Cancer Research Tech Ltd | Immunotherapy for cancer |
| MX2024010956A (es) | 2022-03-09 | 2024-09-17 | Astrazeneca Ab | Moleculas de union contra fra. |
| MA71241A (fr) | 2022-06-27 | 2025-04-30 | Astrazeneca Ab | Combinaisons impliquant des inhibiteurs de tyrosine kinase du récepteur du facteur de croissance épidermique pour traiter le cancer |
| TW202448517A (zh) | 2023-02-16 | 2024-12-16 | 瑞典商阿斯特捷利康公司 | 用治療性結合分子治療癌症的組合療法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5627165A (en) | 1990-06-13 | 1997-05-06 | Drug Innovation & Design, Inc. | Phosphorous prodrugs and therapeutic delivery systems using same |
| EP1523493B1 (de) | 2002-07-09 | 2013-09-04 | Dömling, Alexander | Neue tubulysinanaloga |
| WO2004005326A2 (de) | 2002-07-09 | 2004-01-15 | Morphochem Aktiengellschaft Fu | Tubulysinkonjugate |
| DE10254439A1 (de) | 2002-11-21 | 2004-06-03 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Tubulysine, Herstellungsverfahren und Tubulysin-Mittel |
| EP2517730A3 (en) | 2003-01-27 | 2013-01-02 | Endocyte, Inc. | Vitamin receptor binding drug delivery conjugates |
| CN101678124A (zh) | 2007-03-14 | 2010-03-24 | 恩多塞特公司 | 结合配体连接的微管溶素递药缀合物 |
| DE102009032972A1 (de) | 2009-07-14 | 2011-01-20 | Erbe Elektromedizin Gmbh | Vorrichtung zur Herstellung von Anastomosen |
| WO2011069116A1 (en) | 2009-12-04 | 2011-06-09 | Endocyte, Inc. | Binding ligand linked drug delivery conjugates of tubulysins |
| US20120322741A1 (en) | 2010-02-25 | 2012-12-20 | Purdue Research Foundation | Psma binding ligand-linker conjugates and methods for using |
| EP2600866A4 (en) * | 2010-08-06 | 2013-12-11 | Endocyte Inc | PROCESS FOR THE PRODUCTION OF TUBULYSINES |
-
2011
- 2011-08-05 EP EP11815381.6A patent/EP2600866A4/en not_active Withdrawn
- 2011-08-05 BR BR112013003004A patent/BR112013003004A2/pt not_active IP Right Cessation
- 2011-08-05 SG SG2013008909A patent/SG187728A1/en unknown
- 2011-08-05 AU AU2011285532A patent/AU2011285532B2/en not_active Ceased
- 2011-08-05 EA EA201390203A patent/EA025471B1/ru not_active IP Right Cessation
- 2011-08-05 CA CA2807511A patent/CA2807511A1/en not_active Abandoned
- 2011-08-05 US US13/814,336 patent/US8889880B2/en not_active Expired - Fee Related
- 2011-08-05 MX MX2013001402A patent/MX2013001402A/es active IP Right Grant
- 2011-08-05 JP JP2013524130A patent/JP2013535220A/ja not_active Ceased
- 2011-08-05 KR KR1020137004980A patent/KR20130096712A/ko not_active Ceased
- 2011-08-05 WO PCT/US2011/046797 patent/WO2012019123A1/en not_active Ceased
- 2011-08-05 CN CN201180048479.0A patent/CN103140227B/zh not_active Expired - Fee Related
-
2014
- 2014-10-20 US US14/518,568 patent/US9273091B2/en not_active Expired - Fee Related
-
2016
- 2016-02-26 US US15/054,342 patent/US9499849B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN103140227A (zh) | 2013-06-05 |
| EP2600866A4 (en) | 2013-12-11 |
| EP2600866A1 (en) | 2013-06-12 |
| US20150225447A1 (en) | 2015-08-13 |
| US20160177363A1 (en) | 2016-06-23 |
| EA025471B1 (ru) | 2016-12-30 |
| US20130137139A1 (en) | 2013-05-30 |
| AU2011285532B2 (en) | 2015-09-10 |
| WO2012019123A1 (en) | 2012-02-09 |
| JP2013535220A (ja) | 2013-09-12 |
| US9499849B2 (en) | 2016-11-22 |
| KR20130096712A (ko) | 2013-08-30 |
| US9273091B2 (en) | 2016-03-01 |
| CA2807511A1 (en) | 2012-02-09 |
| AU2011285532A1 (en) | 2013-02-21 |
| CN103140227B (zh) | 2016-01-20 |
| EA201390203A1 (ru) | 2013-08-30 |
| SG187728A1 (en) | 2013-03-28 |
| US8889880B2 (en) | 2014-11-18 |
| BR112013003004A2 (pt) | 2016-06-14 |
| HK1185558A1 (zh) | 2014-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2013001402A (es) | Proceso para preparar tubulisinas. | |
| MD20150091A2 (ro) | Compuşi antivirali | |
| SG190785A1 (en) | Antiviral compounds | |
| MX349004B (es) | Nuevos compuestos. | |
| MY168300A (en) | Pharmaceutical Composition for Inhalation | |
| AU2013225533A8 (en) | Amido spirocyclic amide and sulfonamide derivatives | |
| PH12014501258A1 (en) | Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof | |
| PH12014501514A1 (en) | New azetidine derivatives, pharmaceutical compositions and uses thereof | |
| IN2015DN01119A (enExample) | ||
| MX2013004061A (es) | Analogos de ciclosporina. | |
| PH12014502032A1 (en) | Treatment of brain cancer | |
| MX2014004196A (es) | Citramida de rasagilina. | |
| MX2014010433A (es) | Nueva forma cristalina de sulfato de sitagliptina. | |
| PL402710A1 (pl) | Kompozycje farmaceutyczne zawierajace imatinib lub jego farmaceutycznie dopuszczalna sól oraz sposoby ich otrzymywania | |
| MX348393B (es) | Polimorfo de rifaximina y proceso para la preparacion del mismo. | |
| MX2013004062A (es) | Analogos de ciclosporina. | |
| IN2014DN03010A (enExample) | ||
| WO2012061012A3 (en) | 4-amino-2h-pyran-2-one analogs as anticancer agents | |
| PH12013500210A1 (en) | Highly crystalline valsartan | |
| MX348841B (es) | Derivados de pirimidooxazocina como inhibidores de mtor. | |
| MX2013003859A (es) | Polimorfos de picropodofilina b o c para su uso en la terapia del cancer. | |
| IN2013MU03317A (enExample) | ||
| MX351961B (es) | Analogos de diazonamida. | |
| MX2013005624A (es) | Nuevos derivados de indolizina, su preparacion y su aplicacion en terapeutica. | |
| TN2013000035A1 (en) | Highly crystalline valsartan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |